Castle Biosciences Operating Income

Castle Biosciences (CSTL) currently reports a operating income of $-25M as of June 2026. That compares with $-23M in the prior-year period — down 8.7% year over year. Use the charts on this page to explore Castle Biosciences's operating income history and peer comparisons.

Castle Biosciences's operating income decreased from $-23M to $-25M — a 8.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Castle Biosciences reported $-25M in operating income as of June 2026. That compares with $-23M in the prior-year period — down 8.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-25M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Castle Biosciences, and consider following CSTL for alerts when major investors trade the stock.

Castle Biosciences is classified in the Healthcare sector. On operating income, it currently shows $-25M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CSTL with unrelated industries.